Repurposing of antitumor drug candidate Quisinostat lead to novel spirocyclic antimalarial agents

Ruoxi Li,Dazheng Ling,Tongke Tang,Zhenghui Huang,Manjiong Wang,Fei Mao,Jin Zhu,Lubin Jiang,Jian Li,Xiaokang Li
DOI: https://doi.org/10.1016/j.cclet.2020.12.023
IF: 9.1
2021-05-01
Chinese Chemical Letters
Abstract:<p>Antimalarial chemotherapies endowed with effectiveness against drug-resistant parasites and good safety are urgently required in clinical. Our previous research revealed that clinical phase Ⅱ antitumor drug Quisinostat was a promising antimalarial prototype by inhibiting the activity of <em>Plasmodium falciparum</em> (<em>P. falciparum</em>) histone deacetylase (<em>Pf</em>HDAC). Herein, 30 novel spirocyclic linker derivatives were designed and synthesized based on Quisinostat as lead compound, and then their antimalarial activities and cytotoxicity were systematically evaluated. Among them, compounds <strong>8</strong> and <strong>27</strong> could effectively eliminate wild-type and multi-drug resistant <em>P. falciparum</em> parasites, and display weakened cytotoxicity and good metabolic stability. Western blot assay demonstrated that they could inhibit <em>Pf</em>HDAC activity like Quisinostat. In addition, both <strong>8</strong> and <strong>27</strong> showed certain antimalarial efficacy in rodent malaria model, and the animal toxicity of <strong>8</strong> was significantly improved compared with Quisinostat. Overall, <strong>8</strong> and <strong>27</strong> were structurally novel <em>Pf</em>HDAC inhibitors and provided prospective prototype for further antimalarial drug research.</p>
chemistry, multidisciplinary
What problem does this paper attempt to address?